Evidence map›Paper›PMID 41761752›Full record

ReviewJournal of neuroscience research2026

Chondroitin Sulfate Proteoglycans in CNS Development and Pathophysiology.

Seyed Mojtaba Hosseini, Soheila Karimi-Abdolrezaee

Abstract readReview
In one paragraph

Review in Journal of neuroscience research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Seyed Mojtaba HosseiniDepartment of Physiology and Pathophysiology, Manitoba Multiple Sclerosis Research Center, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Soheila Karimi-AbdolrezaeeDepartment of Physiology and Pathophysiology, Manitoba Multiple Sclerosis Research Center, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

Funding

CIHR PJT-186168CIHR PJT-191850Wings for Life WFL-CA-07/22
6 · The paper itself

Abstract

Chondroitin sulfate proteoglycans (CSPGs) are major components of the matrix in many tissues including the central nervous system (CNS). Interactions between extracellular CSPGs and different cell types are crucial for the development of the CNS as CSPGs are heavily involved in maintaining the pool of progenitors, neurogenesis, neuronal migration and maturation, cortical lamination, synapse formation and stabilization, neuronal plasticity, and memory formation. CSPGs play distinct roles in CNS development and pathology. While physiologic levels of CSPGs have key roles in CNS development, CNS pathologies result in upregulation of CSPGs that pose a barrier to neuroregeneration. Extensive evidence shows that pathologic CSPGs interfere with various regenerative mechanisms including axonal elongation, immunomodulation, synaptogenesis, cellular replacement, and remyelination. At the cellular level, CSPGs' effects are mainly mediated through activation of leukocyte common antigen-related receptor (LAR) and protein tyrosine phosphatase sigma (PTP-σ) receptors. Various approaches have been developed to overcome the inhibitory effects of pathologic CSPGs including enzymatic degradation of CSPGs, blocking CSPG/LAR/PTP-σ axis, and inhibition of CSPGs synthesis. Here, we will discuss the current understanding on the role and mechanisms of CSPGs in CNS development and pathologies and signaling pathways that mediate CSPGs' effects in the CNS. We will also review how CSPGs have been modulated in neurological disorders.

Indexed as

Central Nervous SystemCentral Nervous System DiseasesChondroitin Sulfate ProteoglycansAnimalsHumansNeurodevelopmentNeurogenesisChondroitin Sulfate Proteoglycanscentral nervous systemchondroitin sulfate proteoglycansneurodevelopmentneuropathologysignaling and mechanisms

Identifiers

PMID41761752
PMCPMC12949430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.